In Brief: Biotech process patents
Biotech process patents: HR 587, introduced Jan. 19 by Rep. Moorhead (R-Calif.) and co-sponsored by Rep. Boucher (D-Va.), resembles HR 4307, which passed the House Sept. 20. The bill would amend the patent code to allow a "'biotechnological process' using or resulting in a composition of matter that is novel" to be considered non-obvious if it either makes or uses a product that is novel and non-obvious. Moorhead says in floor statement he intends to schedule action "early this session"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth